European Journal of Dermatology
MENUInfliximab-induced bullous pemphigoid and anti-desmoglein 3 and anti-BP180 autoantibodies in a patient with ulcerative colitis Volume 29, numéro 1, January-February 2019
Illustrations
Division of Dermatology, Department of Medicine of Sensory and Motor Organs, Faculty of Medicine, Tottori University, Yonago, Japan
- DOI : 10.1684/ejd.2018.3431
- Page(s) : 88-90
- Année de parution : 2019
Infliximab, an anti-tumour necrosis factor alpha (TNF-α) agent, is used for treatment of various inflammatory diseases. Infliximab has been reported to induce autoimmune disorders as adverse side effects. Bullous pemphigoid (BP) is an acute or chronic autoimmune skin disease that has occasionally developed after anti-TNF agent administration [1-6]. Here, we report the first case of BP triggered by anti-TNF-α treatment in a patient with ulcerative colitis in whom both anti-desmoglein (Dsg) 3 and anti-BP180 [...]